Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Revenue projections:

Revenue projections for CIPLA
Revenue projections for CIPLA

Investors may be wary of CIPLA as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 0.000000
forwardPE 23.812323
debtToEquity 1.404000
earningsGrowth 0.102000
revenueGrowth 0.032000
grossMargins 0.666910
operatingMargins 0.223110
trailingEps 66.750000
forwardEps 63.540000

Cipla Limited's Forward PE is positioned well, reflecting a favorable balance between stock price and earnings. The stock isn't overpriced, offering room for growth and making it a potentially rewarding investment as its value has room to rise further.
With positive gross and operating margins, Cipla Limited's profitability is evident. These metrics suggest the company is efficiently managing its expenses while maintaining strong revenue, highlighting a solid financial foundation.
With Cipla Limited's forward EPS lower than its trailing EPS, the company is expected to experience a drop in profitability. This suggests a potential slowdown in financial performance compared to the previous year.

Price projections:

Price projections for CIPLA
Price projections for CIPLA

CIPLA's price projections have been gradually revised upward, reflecting increased confidence in the company's future performance. This trend suggests analysts expect CIPLA to achieve greater success in the coming periods.

Insider Transactions:

Insider Transactions for CIPLA
Insider Transactions for CIPLA


CIPLA experienced 2 sell transactions with market price of 1590.4249877929688 per share.There were no sell transactions during the given timeframe.The higher number of buys versus sells near Cipla Limited's current price suggests optimism among investors. This buying trend could be interpreted as a sign that the market expects favorable outcomes for the stock in the near future.

Recommendation changes over time:

Recommendations trend for CIPLA
Recommendations trend for CIPLA


With analysts showing a buy bias for CIPLA, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning CIPLA as a safe and profitable place for investors to allocate their funds and seek growth.